Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Share-based Compensation (2016 - 2025)

Standard Biotools (LAB) has disclosed Share-based Compensation for 16 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 71.43% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.7 million through Dec 2025, down 30.46% year-over-year, with the annual reading at $29.6 million for FY2025, 6.68% down from the prior year.
  • Share-based Compensation for Q4 2025 was $5.7 million at Standard Biotools, down from $7.5 million in the prior quarter.
  • The five-year high for Share-based Compensation was $20.1 million in Q4 2024, with the low at $1.7 million in Q4 2022.
  • Average Share-based Compensation over 5 years is $6.2 million, with a median of $4.6 million recorded in 2024.
  • The sharpest move saw Share-based Compensation skyrocketed 478.56% in 2024, then crashed 71.43% in 2025.
  • Over 5 years, Share-based Compensation stood at $11.7 million in 2021, then tumbled by 85.68% to $1.7 million in 2022, then soared by 106.72% to $3.5 million in 2023, then surged by 478.56% to $20.1 million in 2024, then plummeted by 71.43% to $5.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $5.7 million, $7.5 million, and $5.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.